Reported 8 months ago
As of June 23, 2024, the weight loss drug market battle has begun, with over 120 drugs in development worldwide. The unique mechanisms of these drugs have attracted attention, highlighting the competition for Taiwanese factories to secure a position in this market. Popular approved drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) target obesity with GIP/GLP-1 receptor agonists, affecting hunger control and fat breakdown. Stay tuned for updates on the economic impact of the World Bank's GDP growth forecast adjustment and strong investment in electric vehicles.
Source: YAHOO